• Title/Summary/Keyword: adverse vaccine reaction

Search Result 23, Processing Time 0.028 seconds

Comparison of local reaction at injection site following intramuscular administration with three commercial atrophic rhinitis vaccines in pigs

  • Kim, Myung-Hyee;Kwon, Taeyong;Yoo, Sung J.;Seo, Sang won;Park, Jun Woo;Lyoo, Young S.
    • Korean Journal of Veterinary Service
    • /
    • v.41 no.4
    • /
    • pp.251-255
    • /
    • 2018
  • Bordetella bronchiseptica and Pasteurella multocida are two main pathogens responsible for atrophic rhinitis (AR), which causes considerable economic losses in swine industry worldwide. Commercial vaccine has been widely used to prevent the damage from AR in Korea. Adverse effects of vaccination at the injection site have been reported, which results in the numerous complaint from farms. However, data on about local reaction at the injection site remains limited. In this study, we compared the local adverse effects of three commercial vaccines following intramuscular injection. The results showed that no gross lesion was founded at the injection sites of all three vaccines. In histopathologic examination, a various level of lesions was identified. Especially, the local reaction of vaccine including saponin as an adjuvant showed the lowest level of histopathological lesions, when compared to those of oil-based and vitamin E-based vaccines. Therefore, this study would provide the information about the extent of local reaction at the injection site and help the farmer to select AR vaccine in order to avoid adverse reaction due to vaccination.

A study on perceptions of university students about the COVID-19 vaccine (코로나19 백신에 대한 대학생의 인식 조사)

  • Lee, Yeon-Hee;Yang, Ok-Yul
    • Journal of the Health Care and Life Science
    • /
    • v.9 no.1
    • /
    • pp.185-193
    • /
    • 2021
  • This study conducted a survey using Google Survey targeting 415 college students over the age of 20 to investigate college students' perceptions of the COVID-19 vaccine. As a result, the average result of 'I think the COVID-19 vaccination is necessary' for herd immunity was 3.90, and 65.8% of the 'necessity of vaccination' recognized the 'necessity of vaccination', but 35.4% negatively evaluated 'the safety of the vaccine'. showed. As for the intention to vaccinate against COVID-19, 34.7% said 'I will vaccinate as soon as the order arrives'. This showed that the current COVID-19 vaccination is not positive. As the reasons for not wanting to be vaccinated, 65.3% answered 'adverse reaction to the vaccine' and 25.8% 'distrust of the vaccine itself'. In addition, they perceived the vaccine supply between developed and underdeveloped countries as unequal, and the average was 3.94, indicating that they were afraid of adverse reactions to the COVID-19 vaccine. Therefore, in order to more effectively acquire information about the COVID-19 vaccine, research, platform development, and education on publicity methods through the media frequently used by college students are required.

Development of the Information Materials on Vaccine's Safety and Adverse Events (백신제제 안전 사용 정보지 마련을 위한 연구)

  • Ji, Eun-Hee;Park, Ji-Eun;Han, Na-Young;Hong, Jin-Yi;Noh, Hye-Jin;Lee, Hye-Sook;Shin, Wan-Gyun;Oh, Jung-Mi
    • Korean Journal of Clinical Pharmacy
    • /
    • v.20 no.1
    • /
    • pp.56-65
    • /
    • 2010
  • Objective: This study aimed to develop information materials on vaccine's safety and adverse events which can be utilized by healthcare professionals when prescribing, dispensing and administering vaccines and also by non-healthcare professionals such as pharmaceutical distributors of vaccine. Methods: Information materials regarding vaccines from domestic and foreign governmental organizations, academies, medical organizations and pharmaceutical companies were reviewed. Advisory Committee which consisted of experts in the areas of the vaccine's safety verified the contents and the final information material. Results: Based on the collected data, we developed general guidelines including vaccine constituents, safety information and adverse events of each vaccines, storage and handling, and labeling information. The information materials were developed for both healthcare professionals and non-healthcare professionals such as vaccine distributors. Conclusion: Information materials on vaccine's safety and adverse events developed from this study could be utilized to provide useful information on the vaccine to the medical institutions and distributors.

Adverse Events Following Immunizations in Infants Under 1 Year of Age in Lorestan Province, Western Iran

  • Anbari Khatereh;Ghanadi Koruosh;Toulabipour Alireza;Jamebozuorghi Daryuosh;Baharvand Parastoo
    • Journal of Preventive Medicine and Public Health
    • /
    • v.56 no.2
    • /
    • pp.172-179
    • /
    • 2023
  • Objectives: Vaccination is an important intervention for preventing disease and reducing disease severity. Universal vaccination programs have significantly reduced the incidence of many dangerous diseases among children worldwide. This study investigated the side effects after immunization in infants under 1 year of age in Lorestan Province, western Iran. Methods: This descriptive analytical study included data from all children <1 year old in Lorestan Province, Iran who were vaccinated according to the national schedule in 2020 and had an adverse event following immunization (AEFI). Data were extracted from 1084 forms on age, sex, birth weight, type of birth, AEFI type, vaccine type, and time of vaccination. Descriptive statistics (frequency, percentage) were calculated, and the chi-square test and Fisher exact test were used to assess differences in AEFIs according to the abovelisted variables. Results: The most frequent AEFIs were high fever (n=386, 35.6%), mild local reaction (n=341, 31.5%), and swelling and pain (n=121, 11.2%). The least common AEFIs were encephalitis (n=1, 0.1%), convulsion (n=2, 0.2%), and nodules (n=3, 0.3%). Girls and boys only showed significant differences in mild local reactions (p=0.044) and skin allergies (p=0.002). The incidence of lymphadenitis (p<0.001), severe local reaction (p<0.001), mild local reaction (p=0.007), fainting (p=0.032), swelling and pain (p=0.006), high fever (p=0.005), and nodules (p<0.001) showed significant differences based on age at vaccination. Conclusions: Immunization is a fundamental public health policy for controlling vaccine-preventable infectious diseases. Although vaccines such as the Bacillus Calmette-Guérin vaccine, oral poliovirus vaccine, and pentavalent vaccine are well-researched and reliable, AEFIs are inevitable.

New Concepts on Vaccine Development for the Poultry Diseases

  • Han, M.G.
    • Korean Journal of Poultry Science
    • /
    • v.28 no.2
    • /
    • pp.165-172
    • /
    • 2001
  • Vaccination is one of the most important and cost-effective methods of preventing infectious diseases. Over the past decade, scientific in molecular biology and immunology have improved understanding of many diseases and led to the development of novel strategies for vaccination. An ideal vaccine would induce effective immunity specific for the type of infection, have long duration, require minimal or no boosters, have safety, would not induce adverse reaction, and be easy to administer. The desire to meet these criteria has resulted in the development of vaccines that do not depend on the use of the viable disease agent. It is not the intent of this review to give an extensive review of the field of vaccinology, but rather to address characteristics of conventional and genetically engineered vaccines.

  • PDF

Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador

  • Xochitl Sandoval;Rhina Dominguez;Delmy Recinos;Susana Zelaya;Patricia Cativo;Guillermo Horacio Docena
    • Clinical and Experimental Vaccine Research
    • /
    • v.13 no.1
    • /
    • pp.35-41
    • /
    • 2024
  • Purpose: The effectiveness of coronavirus disease 2019 (COVID-19) vaccination schemes and the combination of vaccines of various platforms for administering booster doses is still being studied since it will depend on the population's response to vaccines. We aimed to evaluate the safety, protection, and immunogenicity of the Salvadorean population's third dose booster COVID-19 vaccine and the potential benefit of homologous vs. heterologous regimens. Materials and Methods: This is an analytical observational cohort study in a population aged 18 to 65 years that was primarily vaccinated with AstraZeneca, Sinovac, or Pfizer/BioNTech. Volunteers were recruited (n=223) and followed up for 3 months after receiving the 3rd vaccine (BNT162b2) as a booster. Adverse reactions were monitored, serum anti-spike immunoglobulin G (IgG) was assessed by chemiluminescence, and a polymerase chain reaction was carried out when subjects developed clinical signs. Results: The cohorts finally included 199 participants, and we observed only mild adverse effects in all cohorts. A significant increase in specific IgG levels was found after the booster dose in all cohorts. The heterologous scheme with Sinovac showed the greatest increase in antibody titer, and a decrease was observed in all participants after 3 months. During the follow-up period, 30 participants showed symptomatology compatible with COVID-19, but only four were laboratory-confirmed and they showed mild clinical signs. Conclusion: These findings indicate that the booster doses used were safe and promoted an immediate increase in immunogenicity, which decreased over time. The heterologous regimen showed stronger immunogenicity compared to the messenger RNA-based homologous scheme.

Utilization of multivalent vaccine on sows ante partum for the prevention of piglet enteritis

  • Oh, Yeonsu;Kim, Myung-Hyee;Han, Jeong-Hee
    • Korean Journal of Veterinary Service
    • /
    • v.40 no.2
    • /
    • pp.133-137
    • /
    • 2017
  • Three swine farms which were suffering from slight economic loss due to suckling piglets' diarrhea, were selected to apply commercialized multivalent vaccine for sow use; $SUISENG^{(R)}$ (Hipra, Spain). Farms were pre-diagnosed with clinical symptoms and molecular detection of C. perfringens Type A and C and E. coli pili by PCR. Sows were vaccinated twice 2 ml of the vaccine at 6 and 3 weeks ante partum intramuscularly according to the manufacturer's instruction. All vaccinated sows did not show any adverse reaction or clinical signs; hypersensitivity, fever, granuloma or abscess on the injection site, appetite loss, and so on. Also, no reproductive disorder was appeared in vaccinated sows compared with non-vaccinated control sows. The results suggested that piglets born from vaccinated sows show significantly better performance in regard of the diarrhea index and mean daily weight gain compared with piglets from non-vaccinated sows. Therefore, the commercial vaccine for the prevention of neonatal diarrhea is found to be effective in reducing diarrhea in the first suckling period of piglets after birth.

Purification of Diphtheia Toxin and the Production of Detoxificated Toxoid Vaccine (디프테리아 toxin 정제와 무독화 toxoid 백신 생산)

  • Cho, Min;Ryu, Yeon-Woo
    • KSBB Journal
    • /
    • v.14 no.2
    • /
    • pp.248-254
    • /
    • 1999
  • Adverse reactions after injection of diphtheria vaccine are induced by impurities present in crude toxoids that cannot be removed completely by purification of toxoids after formalization. To increase toxoid purity, toxin purification was tried before formalization. Crude toxin was purified with ultrafiltration and ion-exchange chromatography. Purified toxin purity was improved 2.9 times higher than crude toxin, and purity was 2,560 Lf/mg PN. Purified toxin was detoxified with formalin and lysine, and potency test were performed. Toxoid, prepared from toxin treated with formalin and lysine, did not show reversion to toxin and purity was higher than the toxoid purified after formalization. Therefore, we concluded that the use of toxoid vaccine prepared from toxin purified is a useful method of minimize adverse reaction after injection of diphtheria vaccine.

  • PDF

Immunogenicity and Safety of Inactivated Influenza Vaccine in Healthy Korean Children and Adolescent (한국의 건강한 소아청소년을 대상으로 한 인플루엔자 사백신의 면역원성과 안전성 연구)

  • Ri, Soohyun;Kim, Mi Jeong;Kim, Yun-Kyung
    • Pediatric Infection and Vaccine
    • /
    • v.25 no.1
    • /
    • pp.35-44
    • /
    • 2018
  • Purpose: This study aimed to evaluate the immunogenicity and safety of a trivalent inactivated influenza vaccine (TIV) among healthy Korean children and adolescents. Methods: From October to December 2008, 65 healthy patients aged 6 months to 18 years who visited Korea University Ansan Hospital for influenza vaccination were enrolled in this study. We measured the hemagglutinin inhibition antibody titers at baseline and 30 days after vaccinating enrollees with split influenza vaccine and calculated the seroprotection rates, geometric mean titers, and seroconversion rates. Local and systemic adverse events were assessed after vaccination. Results: The seroprotection rates against all three viral strains (A/H1N1, A/H3N2, B) were 87.7%, 89.2%, and 89.2% (${\geq}70%$), respectively; seroconversion rates were 44.6%, 73.8%, and 63.1% (${\geq}40%$), respectively; and seroconversion factors were 4.5, 8.4, and 10.5 (>2.5), respectively. The TIV immunogenicity was acceptable according to the CPMP (Committee for Proprietary Medicinal Products) criteria. Although 48 patients (73.8%) reported one or more adverse events, no severe adverse events such as anaphylaxis and convulsion were observed. Forty-two patients (64.6%) reported a local skin reaction, including redness (29.2%), pain (43.1%), or swelling (41.5%) of the injected site, and 26 (40.0%) reported a systemic reaction: fatigue (23.1%), myalgia (20.0%), headache (10.8%), arthralgia (10.8%), chills (9.2%), or fever (7.7%). Conclusions: This study shows that the immunogenicity of the TIV vaccine is acceptable. As there were no serious adverse events aside from local reactions and mild systemic reactions, this vaccine can be safely used among healthy Korean children and adolescents.